Cite
HARVARD Citation
Liu, L. et al. (2021). A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia & lymphoma. 62 (12), pp. 3043-3046. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Liu, L. et al. (2021). A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia & lymphoma. 62 (12), pp. 3043-3046. [Online].